The gene editing tool known as CRISPR-Cas9 is changing what’s possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address ...
Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...
The CRISPR gene editing technique has had a dramatic influence on biomedical research, and has even been applied to a few ...
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...
Cardiologist and Men's Health advisory board member Christopher Kelly, MD, says this treatment is "approaching magic" for ...
News-Medical.Net on MSN
Timing of genetic mutation dictates childhood leukemia aggressiveness
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...
Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...
Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an ...
A new paper from the University of Kansas overturns the idea that a "risk gene" carried by millions of people worldwide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback